ECSP23001748A - Metil (r)–2–(fluorometil)–5–oxo–4–fenil–4,5,6,7–tetrahidro–1h–ciclopenta[b]piridin–3–carboxilato y metil (r)–2–(fluorometil)–5–oxo–4–fenil–1,4,5,7–tetrahidrofuro[3,4–b]piridin–3–carboxilato como activadores de cav1.2 - Google Patents

Metil (r)–2–(fluorometil)–5–oxo–4–fenil–4,5,6,7–tetrahidro–1h–ciclopenta[b]piridin–3–carboxilato y metil (r)–2–(fluorometil)–5–oxo–4–fenil–1,4,5,7–tetrahidrofuro[3,4–b]piridin–3–carboxilato como activadores de cav1.2

Info

Publication number
ECSP23001748A
ECSP23001748A ECSENADI20231748A ECDI202301748A ECSP23001748A EC SP23001748 A ECSP23001748 A EC SP23001748A EC SENADI20231748 A ECSENADI20231748 A EC SENADI20231748A EC DI202301748 A ECDI202301748 A EC DI202301748A EC SP23001748 A ECSP23001748 A EC SP23001748A
Authority
EC
Ecuador
Prior art keywords
syndrome
fluoromethyl
methyl
activators
disorder
Prior art date
Application number
ECSENADI20231748A
Other languages
English (en)
Inventor
Danuta Lubicka
Tejaskumar Pankajbhai Pathak
Sung David C Kim
Zaixing Li
Xilin Zhou
Amir Masoud Sadaghiani
Chui Lu
James Neef
Hye-Yeon Park
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP23001748A publication Critical patent/ECSP23001748A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación proporciona un compuesto de acuerdo con la fórmula (I) o una sal farmacéuticamente aceptable de este como activadores de CaV1.22 para el tratamiento de esquizofrenia, trastorno bipolar, trastorno depresivo mayor, trastorno debido al uso de sustancias, TDAH, síndrome de Phelan–McDermid, trastornos del espectro autista, esclerosis múltiple, demencia frontotemporal, enfermedad de Alzheimer, síndrome de Brugada, síndrome de QT corto, o síndrome de repolarización precoz.
ECSENADI20231748A 2020-06-15 2023-01-10 Metil (r)–2–(fluorometil)–5–oxo–4–fenil–4,5,6,7–tetrahidro–1h–ciclopenta[b]piridin–3–carboxilato y metil (r)–2–(fluorometil)–5–oxo–4–fenil–1,4,5,7–tetrahidrofuro[3,4–b]piridin–3–carboxilato como activadores de cav1.2 ECSP23001748A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/096177 WO2021253180A1 (en) 2020-06-15 2020-06-15 Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators

Publications (1)

Publication Number Publication Date
ECSP23001748A true ECSP23001748A (es) 2023-03-31

Family

ID=76523252

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20231748A ECSP23001748A (es) 2020-06-15 2023-01-10 Metil (r)–2–(fluorometil)–5–oxo–4–fenil–4,5,6,7–tetrahidro–1h–ciclopenta[b]piridin–3–carboxilato y metil (r)–2–(fluorometil)–5–oxo–4–fenil–1,4,5,7–tetrahidrofuro[3,4–b]piridin–3–carboxilato como activadores de cav1.2

Country Status (22)

Country Link
US (3) US11919911B2 (es)
EP (1) EP4165047A1 (es)
JP (2) JP7601911B2 (es)
KR (2) KR20250123945A (es)
CN (3) CN115836076B (es)
AR (1) AR122615A1 (es)
AU (1) AU2021293976B2 (es)
BR (1) BR112022025212A2 (es)
CA (1) CA3182354A1 (es)
CL (1) CL2022003525A1 (es)
CO (1) CO2022017502A2 (es)
CR (1) CR20230008A (es)
DO (1) DOP2022000276A (es)
EC (1) ECSP23001748A (es)
IL (1) IL298448B1 (es)
JO (1) JOP20220337A1 (es)
MX (1) MX2022015866A (es)
PE (1) PE20231079A1 (es)
PY (1) PY2147607A (es)
TW (1) TW202214651A (es)
UY (1) UY39265A (es)
WO (2) WO2021253180A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
AR122613A1 (es) * 2020-06-16 2022-09-21 Novartis Ag Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activadores de cav1.2
CN118510782A (zh) * 2021-12-13 2024-08-16 诺华股份有限公司 作为CaV1.2激活剂的吡啶-3-甲酸酯化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
WO1983004023A1 (en) 1982-05-10 1983-11-24 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds
EP0111455A3 (de) 1982-12-10 1984-07-25 Ciba-Geigy Ag Ungesättigte Lactone
CN1013496B (zh) * 1984-03-23 1991-08-14 拜尔股份公司 1-烷基取代的1，4-二氢吡啶内酯化合物的制备方法
DE3410645A1 (de) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US4567268A (en) * 1984-04-03 1986-01-28 Merck & Co., Inc. Process for preparation of certain tetrahydrofuro[3,4-b]pyridines
US6518279B2 (en) * 1999-03-04 2003-02-11 Abbott Laboratories Cyclopentanone dihydropyridine compounds useful as potassium channel openers
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
MA44008A (fr) * 2016-02-10 2018-12-19 Janssen Pharmaceutica Nv 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN116392609A (zh) 2017-03-23 2023-07-07 Dnarx公司 用于体内核酸表达的系统和方法
JP2020523309A (ja) * 2017-06-08 2020-08-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ピラゾロピリミジンｐｄｅ９インヒビター
WO2020242245A1 (ko) * 2019-05-29 2020-12-03 에스티팜 주식회사 프탈라진온 화합물 및 이들의 용도
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
AR122613A1 (es) 2020-06-16 2022-09-21 Novartis Ag Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activadores de cav1.2

Also Published As

Publication number Publication date
US20250304594A1 (en) 2025-10-02
CN115836076A (zh) 2023-03-21
WO2021255607A1 (en) 2021-12-23
PY2147607A (es) 2022-03-15
US20250002499A1 (en) 2025-01-02
JP7601911B2 (ja) 2024-12-17
DOP2022000276A (es) 2023-01-15
AR122615A1 (es) 2022-09-21
CN120267664A (zh) 2025-07-08
PE20231079A1 (es) 2023-07-17
CR20230008A (es) 2023-01-25
WO2021253180A1 (en) 2021-12-23
JP7848294B2 (ja) 2026-04-20
US12365690B2 (en) 2025-07-22
CO2022017502A2 (es) 2022-12-20
IL298448B1 (en) 2026-03-01
AU2021293976B2 (en) 2023-12-14
CA3182354A1 (en) 2021-12-23
US20210395261A1 (en) 2021-12-23
CN115836076B (zh) 2025-04-25
TW202214651A (zh) 2022-04-16
AU2021293976A1 (en) 2022-11-24
CN120267665A (zh) 2025-07-08
IL298448A (en) 2023-01-01
JOP20220337A1 (ar) 2022-12-13
KR20230022982A (ko) 2023-02-16
BR112022025212A2 (pt) 2023-01-03
JP2025032216A (ja) 2025-03-11
UY39265A (es) 2022-01-31
US11919911B2 (en) 2024-03-05
KR20250123945A (ko) 2025-08-18
KR102845488B1 (ko) 2025-08-13
MX2022015866A (es) 2023-01-24
JP2023530917A (ja) 2023-07-20
CL2022003525A1 (es) 2023-08-11
EP4165047A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
DOP2022000276A (es) Metil (r)–2–(fluorometil)–5–oxo–4–fenil–4,5,6,7–tetrahidro–1h–ciclopenta[b]piridin–3–carboxilato y metil (r)–2–(fluorometil)–5–oxo–4–fenil–1,4,5,7–tetrahidrofuro[3,4–b]piridin–3–carboxilato como activadores de cav1.2
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
UY40470A (es) Compuestos tricíclicos y sus usos
UY39261A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
JP2015537020A5 (es)
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
AR127254A1 (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
PE20200793A1 (es) Compuestos de cetonas biciclicas sustituidas, como inhibidores de la rip1 cinasa y composiciones farmaceuticas que los comprenden
AR119614A1 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
MX2025006990A (es) Compuesto quimerico protac, metodo de preparacion del mismo y uso del mismo
AR126077A1 (es) Compuestos de pirrolil-sulfonamida
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
PY2147613A (es) COMPUESTOS DE METIL 2–METIL–5–OXO–1,4,5,7–TETRAHIDROFURO[3,4–b]PIRIDINA–3–CARBOXILATO COMO ACTIVADORES DE CAV1.2
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR078358A1 (es) Uso de derivados de indol como activadores de nurr-1 para la aplicacion como un producto medicinal destinado al tratamiento de la enfermedad de parkinson
AR130252A1 (es) Inhibidores enzimáticos
UY28119A1 (es) Nuevos derivados que contienen fosforo
AR113794A1 (es) Inhibidores de trpc6
UY39971A (es) Una nueva clase de fármacos antivirales